Abstract
Body mass index (BMI), which represents the proportion of weight to height, is a controversial prognostic factor for acute myeloid leukemia (AML). We evaluated prognostic value of BMI in Japanese AML. The study included 369 adult patients with newly diagnosed AML who were administered either daunorubicin or idarubicin with cytarabine as induction chemotherapy. The patients were categorized into two groups according to their BMI: the NW group (BMI < 25.0 kg/m2; normal and underweight) and OW group (BMI ≥ 25.0 kg/m2; overweight and obese). We analyzed treatment efficacy and toxicity of induction chemotherapy, and survival outcomes in each group. Patients in the OW group showed a better complete remission rate than the NW group (86.1 versus 76.5%, P = 0.045), no early death (0.0 versus 4.1%, P = 0.042), and better overall survival (OS) at 3 years (62.2 versus 50.1%, P = 0.012). Multivariate analysis showed BMI is an independent prognostic factor for OS (hazard ratio 0.62, 95% confidence interval 0.42–0.92, P = 0.017). These results indicate the prognostic value of BMI in adult AML patients.
Similar content being viewed by others
References
Yoshiike N, Miyoshi M. Epidemiological aspects of overweight and obesity in Japan–international comparisons. Nihon Rinsho. 2013;12(71):207–16.
WHO Technical Report Series 854. Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organization, Geneva 1995.
Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008;371:569–78.
Lewis CE, McTigue KM, Burke LE, Poirier P, Eckel RH, Howard BV, et al. Mortality, Health Outcomes, and Body Mass Index in the Overweight Range. Circulation. 2009;119:3263–71.
De Pergola G, Silvestris F. Obesity as a Major Risk Factor for Cancer. J Obes. 2013;2013:291546.
Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293:203–11.
Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G, et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1612 patients entered into the MRC AML 10 trial. Blood. 1998;92:2322–33.
Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET, et al. Toxicity and response criteria of the eastern cooperative oncology group. Am J Clin Oncol. 1982;5:649–55.
Ohtake S, Miyawaki S, Fujita H, Kiyoi H, Shinagawa K, Usui N, et al. Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: the JALSG AML201 Study. Blood. 2011;24(117):2358–65.
Miyawaki S, Ohtake S, Fujisawa S, Kiyoi H, Shinagawa K, Usui N, et al. A randomized comparison of 4 courses of standard-dose multiagent chemotherapy versus 3 courses of high-dose cytarabine alone in postremission therapy for acute myeloid leukemia in adults: the JALSG AML201 Study. Blood. 2011;24(117):2366–72.
Yamazaki E, Kanamori H, Itabashi M, Ogusa E, Numata A, Yamamoto W, et al. Hyper-recovery of platelets after induction therapy is a predictor of relapse-free survival in acute myeloid leukemia. Leukemia Lymphoma. 2017;58(1):104–9.
Cheson BD, Bennett JM, Kopecky KJ, Büchner T, Willman CL, Estey EH, et al. Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol. 2004;21:4642–9.
Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. Am Stat Assoc J. 1958;53:457–81.
Cox DR. Regression models and life tables. J R Stat Soc Series B Stat Methodol. 1972;34:187–220.
Kanda Y. Investigation of the freely-available easy-to-use software “EZR” (Easy R) for medical statistics. Bone Marrow Transplant. 2012;2013:48,452–48,458. doi:10.1038/bmt.2012.244 (Advance online publication 3).
Nazare JA, Smith J, Borel AL, Aschner P, Barter P, Van Gaal L, et al. Usefulness of measuring both body mass index and waist circumference for the estimation of visceral adiposity and related cardiometabolic risk profile (from the INSPIRE ME IAA study). Am J Cardiol. 2015;115:307–15.
Kodama S, Horikawa C, Fujihara K, Yoshizawa S, Yachi Y, Tanaka S, et al. Quantitative relationship between body weight gain in adulthood and incident type 2 diabetes: a meta-analysis. Obes Rev. 2014;15:202–14.
Lange BJ, Gerbing RB, Feusner J, Skolnik J, Sacks N, Smith FO, et al. Mortality in overweight and underweight children with acute myeloid leukemia. JAMA. 2005;293:203–11.
Kanazawa M, Yoshiike N, Osaka T, Numba Y, Zimmet P, Inoue S. Criteria and classification of obesity in Japan and Asia-Oceania. Asia Pac J Clin Nutr. 2002;11(8):732–7.
Rodvold KA, Rushing DA, Tewksbury DA. Doxorubicin clearance in the obese. J Clin Oncol. 1988;6:1321–7.
Krogh-Madsen M, Bender B, Jensen MK, Nielsen OJ, Friberg LE, Honoré PH. Population pharmacokinetics of cytarabine, etoposide, and daunorubicin in the treatment for acute myeloid leukemia. Cancer Chemother Pharmacol. 2012;69:155–1163.
Murry DJ, Riva L, Poplack DG. Impact of nutrition on pharmacokinetics of anti-neoplastic agents. Int J Cancer Suppl. 1998;11:48–51.
Boullata JI. Drug disposition in obesity and protein-energy malnutrition. Proc Nutr Soc. 2010;69:543–50.
Wilkinson GR. Drug Metabolism and Variability among Patients in Drug Response. N Engl J Med. 2005;352:2211–21.
Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol Ther. 2013;138:103–41.
Luskin MR, Lee JW, Fernandez HF, Abdel-Wahab O, Bennett JM, Ketterling RP, et al. Benefits of high dose daunorubicin in AML induction extends across cytogenetic and molecular groups. Blood. 2016;24(127):1551–8.
Medeiros BC, Othus M, Estey EH, Fang M, Appelbaum FR. Impact of body-mass index on the outcome of adult patients with acute myeloid leukemia. Haematologica. 2012;97:1401–4.
Fuji S, Takano K, Mori T, Eto T, Suzuki R, Fukuda T, et al. Impact of pretransplant body mass index on the clinical outcome after allogeneic hematopoietic SCT. Biol Blood Marrow Transplant. 2014;49(12):1505–12.
Le Blanc K, Ringden O, Remberger M. A low body mass index is correlated with poor survival after allogeneic stem cell transplantation. Haematologica. 2003;88:1044–52.
Deeg HJ, Seidel K, Bruemmer B, Pepe MS, Appelbaum FR. Impact of patient weight on non-relapse mortality after marrow transplantation. Bone Marrow Transplant. 1995;15:461–8.
Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, et al. Appropriate chemotherapy dosing for obese adults patients with cancer: American society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2012;30:1553–61.
Acknowledgements
This study was conducted by the Yokohama Cooperative Study Group for Hematology (YACHT) and any of the seven hospitals collaborate to form the Yokohama City University Hematology Group.
Author information
Authors and Affiliations
Consortia
Corresponding author
Ethics declarations
Conflict of interest
Hiroyuki Fujita has the following financial relationship to disclose: Honoraria (manuscript fee) from Chugai Pharmaceutical CO., LTD.
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Ando, T., Yamazaki, E., Ogusa, E. et al. Body mass index is a prognostic factor in adult patients with acute myeloid leukemia. Int J Hematol 105, 623–630 (2017). https://doi.org/10.1007/s12185-017-2183-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12185-017-2183-7